Riboscience to Present Phase 1b Data on RBS2418 at ESMO 2026
News related to:Riboscience LLC · 2 min read
PALO ALTO, Calif., Oct. 19, 2026 /CourierPR/ -- Riboscience, a clinical-stage biotechnology company based in the San Francisco Bay Area, is set to present groundbreaking data from its Phase 1b study of RBS2418, an oral ENPP1 inhibitor, at the European Society for Medical Oncology (ESMO) Congress 2026.
The poster, which will be presented on Saturday, October 24, 2026, at 12:00 CEST, will delve into the safety, pharmacokinetic, pharmacodynamic, and clinical outcome data of RBS2418. Specifically, the study evaluated RBS2418 in a safety population of 89 patients with advanced, unresectable, recurrent, or metastatic solid tumors. The research will also explore the outcomes of RBS2418 in both monotherapy and in combination with approved anti-cancer treatments. Additionally, the poster will present long-term survival outcomes, marking a significant milestone in the development of RBS2418.
RBS2418, a first-in-class oral small-molecule inhibitor of ENPP1, is designed to restore anti-tumor immunity by blocking ENPP1, which is associated with effective cGAMP clearance in the tumor microenvironment, a block of dendritic cell activation, a cold tumor phenotype, and immune evasion. The expression of ENPP1 and cGAS is highly prevalent in solid tumors, and ENPP1 expression on circulating tumor cells has been linked to an increased risk of metastasis.
The poster presentation will also cover the results from two ongoing clinical trials: a Phase 2 trial for late-line colorectal cancer (CRC) (NCT06824064) and a combination therapy trial for first-line hepatocellular carcinoma (HCC) (NCT07175441). These trials are part of Riboscience's broader strategy to advance RBS2418 as a novel immunotherapy for various types of advanced solid tumors.
The presentation is expected to attract significant attention from the oncology community, as it provides insights into the potential of RBS2418 to transform the treatment landscape for advanced solid tumors.
Riboscience's focus on developing selective drug candidates for cancer, joint, and infectious diseases through its proprietary library of nucleoside and non-nucleoside analogs and structure-guided design underscores its commitment to advancing innovative therapies. The company's work with RBS2418 represents a significant step forward in the field of immunotherapy, potentially offering new hope to patients with advanced solid tumors.